Word: seiden
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...would be pointless. Many opponents argue that, even if the bridge is made safer, suicidal people will just kill themselves elsewhere. But according to landmark 1978 study by Richard Seiden of the University of California, Berkeley, that is not necessarily so. Seiden tracked down 515 people who were stopped from jumping off the bridge between 1937 and 1971, and found that an average of 26 years after their suicide attempt, 94% were still alive or had died from natural causes. "When a person is unable to kill himself in a particular way," Seiden wrote, "it may be enough...
...also be effective in preventing heart disease and breast cancer in older women. Clinical trials of the drug's ability to stave off heart attacks begins in May, with testing of the impact on breast cancer to start later this year. The implications could be huge for Lilly. Carl Seiden, an analyst who follows the drug industry for J.P. Morgan Securities, says sales of Evista as an osteoporosis remedy alone could approach $2 billion...
...What Seiden and others claim is that the FDA glossed over evidence that both Redux and the older drug fenfluramine cause significant brain damage in laboratory animals, from mice to baboons. The problem, they say, is that after the drugs are withdrawn, serotonin levels plummet and stay low for weeks at least. The effect is similar to one caused by the recreational drug Ecstasy, a distant chemical cousin of the fenfluramine family, and the cause is evidently the same: neurotoxicity, or more plainly, the killing of brain cells. An overdose of Redux makes the neurons that produce serotonin swell, then...
Hence the November meeting. Bilstad acknowledges that the schedule conflicted with the San Diego neurosciences conference. But since Seiden and other Redux opponents had thoroughly aired their views in September and had no new findings, Bilstad decided to go ahead. Says he: "We weighed the idea of putting off the decision for several months, until those experts could be there. Since the committee had heard their presentations before and were given transcripts, we decided that we had the benefit of their comments on the issues. It was a judgment call...
...advisory committee's recommendation wasn't legally binding on FDA Commissioner David Kessler. Last December 22 neuroscientists, including Seiden and Dr. George Ricaurte of Johns Hopkins, asked the FDA to "forgo a final decision on dexfenfluramine until more information is available on its serotonin-neurotoxic potential in humans." Nevertheless, Kessler gave the go-ahead for Redux last spring...